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Abstract We estimated healthcare costs associated with
patients with type 2 diabetes compared with non-diabetic
subjects in a population-based primary care database
through a retrospective analysis of economic impact during
2011, including 126,811 patients with type 2 diabetes in
Catalonia, Spain. Total annual costs included primary care
visits, hospitalizations, referrals, diagnostic tests, self-
monitoring test strips, medication, and dialysis. For each
patient, one control matched for age, gender and managing
physician was randomly selected from a population data-
base. The annual average cost per patient was €3110.1 and
€1803.6 for diabetic and non-diabetic subjects, respectively
(difference €1306.6; i.e., 72.4 % increased cost). The costs
of hospitalizations were €1303.1 and €801.6 (62.0 %
increase), and medication costs were €925.0 and €489.2
(89.1 % increase) in diabetic and non-diabetic subjects,
respectively. In type 2 diabetic patients, hospitalizations
and medications had the greatest impact on the overall cost
(41.9 and 29.7 %, respectively), generating approximately
70 % of the difference between diabetic and non-diabetic
subjects. Patients with poor glycaemic control (glycated
haemoglobin[7 %;[53 mmol/mol) had average costs of
€3296.5 versus €2848.5 for patients with good control. In
the absence of macrovascular complications, average costs
were €3008.1 for diabetic and €1612.4 for non-diabetic
subjects, while its presence increased costs to €4814.6 and
€3306.8, respectively. In conclusion, the estimated higher
costs for type 2 diabetes patients compared with non-dia-
betic subjects are due mainly to hospitalizations and
medications, and are higher among diabetic patients with
poor glycaemic control and macrovascular complications.
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Introduction
Type 2 diabetes mellitus (T2DM) is a global health prob-
lem due to its high worldwide prevalence, high cost of
treatment, associated chronic complications, disability, and
premature deaths [1]. Its incidence and prevalence in
developed countries has increased in recent decades, and
several studies confirm that this increase will continue [1–
4]. This rising prevalence, together with a progressively
aging population, will significantly increase the use of
healthcare products and services in the near future [5].
Moreover, chronic complications of T2DM have a well-
known negative impact on costs [3, 6, 7] and patients’
quality of life [1, 6, 8].
The high cost of managing T2DM and its associated
complications represents a major economic burden for
healthcare organizations at both the primary and special-
ized level [9]. A recent study conducted in the United
States (US) showed that around 20 % of medical costs are
generated by complications associated with the disease [5].
Among acute complications, severe hypoglycaemia has the
highest cost for the health system [10]. However, late
complications, especially end stage renal disease (ESRD)
requiring dialysis and transplantation, have the greatest
impact on morbidity and mortality [11, 12]. This was
confirmed in a recent study in the US in which cardio-
vascular disease was associated with cost increases of
between 70 % and 150 %, and ESRD with increases up to
500 % [12].
Previous research also indicates that medical costs per
person are much higher in patients with diabetes than in the
general population [13, 14]—a difference due mainly to the
increased use of hospital resources caused by complica-
tions of the disease [1, 5, 12–18]. The results of country-
specific estimates for Spain from the Cost of Diabetes in
Europe–Type 2 (CODE-2) study showed an average annual
healthcare cost per diabetic patient of €1305 in 1999
(equivalent to around €3363 in 2011), including direct
costs [15], with medication, hospitalization and primary
care visits accounting for most of this figure. There was a
1.6-fold increase in patients with microvascular compli-
cations, and a 2.3-fold increase in patients with
macrovascular complications [15].
In Europe, the few studies that have compared health-
care costs between diabetic and non-diabetic populations
have shown an increase in costs of around 60–80 % [13,
14, 19]. However, these studies have some methodological
limitations that make comparisons between groups (dia-
betic vs. non-diabetic patients) difficult, and hinder the
establishment of the costs attributable to type 2 diabetes
with certainty: they included both type 1 and type 2 dia-
betic patients; they excluded treatment with drugs other
than antidiabetic agents; and they were not matched for
age, gender and managing physician.
The present study was conducted to estimate the
resource consumption and additional costs attributable to
T2DM for the Spanish National Health System in 2011 in
comparison with a control group of non-diabetic subjects
matched for age, gender and managing physician, selected
randomly from a population database.
Methods
Research design and subjects
The present Diabetes Mellitus Cost Study (eCostesDM) is a
retrospective study designed to estimate and compare the
costs of patients with T2DM with those of non-diabetic
patients treated at primary care centers in the Catalan
Health Institute (ICS) system in 2011.
Patient selection
All patients aged between 31 and 90 with a diagnosis of
T2DM [International Classification of Diseases (ICD)
codes E11, E14] seen in primary care in 2011 were
included, and all variables recorded during 2011 were
entered in the study following the same criteria as previous
studies [20–22]. Subsequently, an individual matching was
applied in which, for each diabetic patient, one patient not
diagnosed with diabetes was included, and matched on
gender, age (maximum difference of 2 years), and
managing physician. For this, we used a simple random
sampling without replacement: all non-diabetic patients
matching the individual diabetic patient were selected, and
a random number was assigned to each of them. After this,
the subject with the lowest random number was chosen,
and removed from the control population so that it could
not be selected again. Subjects in either group who were
not alive at the end of the study were not included in the
analyses.
Information and variables of interest
Data were extracted from the Information System for the
Development of Research in Primary Care (SIDIAP)
database, which is intended for use in research and includes
the e-CAP medical records of all patients in the Catalan
Health Institute [23, 24].
The Catalan Health Institute (Institut Catala` de la
Salut—ICS) is the main provider of primary healthcare
services in Catalonia. It manages 470 primary care teams
caring for more than 5.5 million citizens, approximately
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83 % of the Catalan population. All ICS primary care
professionals (about 15,000) use the same computerized
medical record program (e-CAP), created and managed by
the institution itself. The ICS also directly manages 8
hospitals while the remaining 58 hospitals in Catalonia are
members of the Network of Hospitals of Public Utilization
(XHUP) (http://www.gencat.cat/ics/english.htm, last
accessed 15 July 2015).
To estimate the consumption of healthcare resources we
used the SIDIAPQ subpopulation, which is composed of
those patients with the most complete medical histories
[23, 24], and includes data from 1,878,816 of the 5.8
million patients registered in the parent SIDIAP database.
This information was supplemented with data registered in
the ConjuntoMı´nimoBa´sico de Datos de AltasHospitalarias
(CMBD_HA; Set of Minimum Basic Data Set of Hospital
Admissions) [25], which records all hospital admissions in
Catalonia. The CMBD follows the recommendations of the
European Minimum Basic Data Committee, and contains
information on clinical records and discharge reports from
hospitals. However, it does not have information about
medical emergencies, including hypoglycemia or visits to
the hospital outpatient’s services.
The analysis included healthcare direct costs of diabetic
patients for the National Health Service. Data on private
healthcare costs for the patients themselves or for their
relatives were not available.
The following direct costs were analyzed in the study:
primary care visits (differentiating between doctor’s or
nurse’s visits, and between place of visit, i.e., in the office
or at home), hospitalizations, referrals to specialist care,
diagnostic tests, medication, dialysis treatment, and use of
self-monitoring test strips. The antidiabetic treatment
variable included three categories: non-pharmacologic
treatment, treatment with non-insulin antidiabetic drugs
only, and treatment with insulin (with or without other
antidiabetic agents). Finally, we did not impute missing
data or modeled censored data. Patients with no registered
costs (not using healthcare resources during the study
period) were not excluded.
Cost calculation
To calculate the costs we used the prices established in the
Official Bulletin of the Catalan Government (DOGC) for
2012 [26]. All costs are expressed in Euros at 2011 prices.
For this, the prices set by the Department of Health were
adjusted to 2011 values by subtracting 0.9 % to account for
inflation [27].
The costs of hospital admissions were obtained using the
Diagnosis-Related Groups (DRG) patient classification
system [28] published in the DOGC [26], and weighted by
level of hospital complexity (high, medium, and low). For
medications, the retail price was used based on the phar-
macy billing information. For self-monitoring test strips,
we used the mean cost per patient in each primary care
team. For the cost of dialysis, the mean frequency was
estimated to be three sessions a week. As information on
the type of dialysis used for each patient was not available,
the cost of each session was weighted according to local
use (20 % peritoneal dialysis, and 80 % haemodialysis)
[29], using the prices established by the DOGC. All the
variables and information on their sources and costs are
shown in the Online Resource (Table S1).
The final costs of the two study populations were cal-
culated as follows: the resources consumed by each indi-
vidual under each of the resource variables were quantified,
and then multiplied by the cost of each resource. This
procedure yielded the total resource cost per individual as
well as the overall cost for each study population (diabetic
subjects vs. subjects without diabetes).
Sensitivity analysis
We performed a deterministic sensitivity analysis by
modifying the value of cost variables corresponding to
hospitalizations and primary care visits. For hospitaliza-
tions, two different calculation methods were used: the
DRG method [28], and the combination of relative inten-
sity of structure (RIS) and relative intensity of resources
(RIR), which weights the complexity of the structure and
the resources to estimate the cost of a hospital discharge
[30]. For the primary care visit cost variable, two methods
were used: one based on the public system costs published
in the DOGC, and the other on the private costs provided
by the Oblikue database [31] (Online Resource, Table S1).
To assess the difference between groups based on prices
used we compared the ratios between T2DM patients and
subjects without diabetes.
Statistical analysis
We compared the mean total cost of resource consumption,
and the mean cost of each individual resource consumed
according to the presence or absence of T2DM. The Gen-
eralized Linear Models (GLM) methodology was used to
study the effect of T2DM on cost, as well as the factors
associated with increased costs in T2DM patients. Given
the asymmetry of the cost variable, we used the Gamma
family and the logarithm as the link function [32].
In the first model, in which we compared diabetic versus
non-diabetic subjects, we used a GLM model with four
steps: first the raw effect of T2DM; second the adjusted
effect for gender and age; third the adjusted effect for
gender, age, cardiovascular disease, and heart failure; and
fourth adding end-stage renal failure (stage 5) or dialysis to
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the third model. For the second analysis, considering only
diabetic patients, a GLM model was estimated including
age, gender, duration of T2DM, antidiabetic treatment,
cardiovascular disease, heart failure, kidney disease,
microvascular complications, obesity, and glycated hemo-
globin HbA1c values. To deal with the high occurrence of
zeros in the observed data (non diabetic group), we used a
hurdle model to count positive outcomes ([0), using
truncated negative binomial regression. Analyses were
performed using SPSS (released 2009. PASW Statistics for
Windows, Version 18.0. SPSS Inc., Chicago IL) and Sta-
taCorp. 2013. (Stata Statistical Software: Release 13. Sta-
taCorp LP, College Station, TX). For the hurdle model, we
used the R-3.2.2 Package ‘pscl’ [33].
Results
The mean ages of the non-diabetic and T2DM populations
were 67.5 years [standard deviation (SD) = 11.6], and
67.6 years (SD = 11.7), respectively. In both groups,
slightly over half (53.5 %) were men. The median duration
of T2DM was 6.2 years (interquartile range 3.2–9.6), and a
mean of 7.2 years (SD = 5.8). Patients with T2DM were
on average more obese, and had more hypertension and
diabetes-related conditions than the control group
(Table 1). Consumption of all resources was increased in
the T2DM group (Table 1).
The estimated annual cost per person in the T2DM
group was €3110.1 [95 % confidence interval (CI)
3065.8–3154.3, median €1548.2; 25 percentile: €825.5; 75
percentile: €2883.4] and €1803.4 (95 % CI 1759.6–1847.3,
median €730; 25 percentile: €261; 75 percentile: €1601) in
the non-diabetic group. The annual cost was 72.4 % higher
in the T2DM group (Table 2). The variables with the
greatest impact on the overall cost in the T2DM group were
hospitalizations (41.9 %), medications (29.7 %), and pri-
mary care visits (18.5 %). Hospitalizations and medica-
tions generated approximately 70 % of the difference in
total annual cost between the two groups. The two other
variables presenting large differences between groups were
specialists’ referrals and diagnostic tests, although they
represented a small proportion of expenditure.
According to gender (Online Resource, Table S2), total
annual costs were higher in men, especially in the T2DM
group: €3143.8 (95 % CI 3080.2–3207.4) in men vs.
€3071.2 (95 % CI 3010.5–3132.0) in women. The variable
with the greatest gender differences between the two
groups were hospitalizations, with an increase in costs in
the T2DM group of €246.9 (95 % CI 472.6–621.6) in men
and €448.9 (95 % CI 354.9–542.9) in women.
There was a progressive increase in costs with increase
in age for all age groups, although in non-diabetic patients
the increase was more pronounced (Online Resource,
Table S3, and Fig. S1). The differences in costs between
patients with and without T2DM narrowed progressively
with increasing age (Online Resource, Fig. S1). As for the
degree of glycaemic control (Table 3), diabetic patients
with poor control (HbA1c [7 %; [53 mmol/mol) had
increased costs of €448.0/patient/year (95 % CI
365.7–530.4) compared to those with good control. The
two main variables causing this increase were medications
€232.9 (95 % CI 220.5–245.3) and hospitalizations €170.4
(95 % CI 92.5–248.2).
Table S4 in the Online Resource shows the effect of
comorbidity and diabetes complications on the increase in
cost per patient. Costs were significantly higher in the T2DM
group for all conditions exceptmicro- andmacroalbuminuria
for which the costs were higher (though not significantly) in
the non-diabetes group. In the absence of cardiovascular
disease, the cost was €3008.1 (95 % CI 2963.8–3052.3) in
diabetic patients and €1612.4 (95 % CI 1566.0–1658.7) in
non-diabetic subjects, while the presence of any cardiovas-
cular disease increased costs to €4814.6 (95 % CI
4683.7–4947.4) and €3306.8 (95 % CI 3173.0–3440.6),
respectively. The complication that produced the greatest
increase was heart failure, reaching €6866.6 (95 % CI
6563.1–7170.1) per year in patients with T2DMcompared to
€4759.2 (95 % CI 4422.6–5095.8) in non-diabetic subjects;
this difference of €2107.4 (95 % CI 1654.2–2560.6) was the
largest difference in costs between the two groups. As
regards antidiabetic treatment, 26.9 % of diabetic patients
received no medication (only lifestyle intervention), 35.4 %
oral monotherapy, 20.2 % oral combination therapy and
16.5 % insulin either alone or in combination with non-in-
sulin antidiabetic medication. The cost of antidiabetic drugs
was €222/patient/year (24 % of the cost of pharmaceutical
prescriptions, and 7.1 % of the total cost).
Estimation of the crude effect of T2DM on healthcare
costs through a multivariate hurdle model (Online
Resource, Table S5) indicated that costs were 54 % higher
in diabetic patients than in non-diabetic subjects. Adjusting
for sociodemographic and clinical variables (age, gender,
cardiovascular disease, heart failure, and end stage renal
disease), the impact of diabetes on healthcare costs
decreased slightly by 13 %, but remained significantly
increased (41 %). This model took into account the dif-
ference in the number of patients with zero direct medical
costs (2 diabetic patients vs. 14,131 non-diabetic subjects).
In the multivariate analysis (GLM model) including
only diabetic patients (Table 4), the variables with the
greatest impact on cost were renal failure, with costs more
than 10 times higher for patients in stage 5 (eGFR\15 or
dialysis), and heart failure, which increased costs by almost
70 %. Treatment with antidiabetic drugs also increased
costs by 11 % in non-insulin-treated and 64 % in insulin-
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treated patients. Costs were 42 % higher in patients with
cardiovascular disease than in those without. Finally, costs
also increased with age in both T2DM and non-diabetic
groups, but the effect of T2DM gradually decreased; the
difference was the largest in patients aged under 46 years
(quotient 3.5) and fell progressively to only 1.4 in those
aged over 80 (Online Resource, Table S5 and Fig. 1).
In the sensitivity analysis, hospital expenditure was
reduced by approximately 50 % in both groups when using
the combination of RIS and RIR method compared to the
DRG method. However, the ratios between T2DM patients
and subjects without diabetes using either price were almost
identical (1.63:1 vs. 1.60:1). In the sensitivity analysis of the
primary care visit costs, the cost decreased in both groups
when using the Oblikue prices [26, 31] compared to the costs
published in the DOGC, but the ratio between groups
remained practically unchanged (1.56:1 vs. 1.62:1).
Discussion
This article reports the costs attributable to T2DM in the
primary care population in Spain. In 2011, the mean annual
cost in patients with T2DM was 72.4 % greater than in
Table 1 Demographic and clinical characteristics, and consumption of healthcare resources in patients with type 2 diabetes mellitus (T2DM) or
without diabetes
Patients with T2DM (n = 126,811) Patients without diabetes (n = 126,811)
Age, mean (SD), years 67.6 (11.7) 67.5 (11.6)
Men (%) 53.5 53.5
Diabetes duration, median (interquartile range), years 6.2 (3.2–9.6) –
HbA1c, mean (SD), % (n = 100,391) 7.1 (1.4) –
HbA1c, mean (SD), mmol/mol, (n = 100,391) 54.1 (12.9) –
BMI (kg/m2) 30.4 (5.3) 28.6 (5.3)
Systolic blood pressure, mean (SD), mmHg 137 (13.7) 134 (13.7)
Diastolic blood pressure, mean (SD), mmHg 76 (8.8) 76 (8.8)
Hypertension (%) 68.7 45.9
LDL-cholesterol, mean (SD), mg/dL 111.5 (32.7) 130.1 (32.2)
Smoking habit (%) 14.8 16.6
Antidiabetic treatment
No pharmacological treatment (%) 26.9 –
Non-insulin antidiabetic drugs (%) 56.2 –
Insulin (alone or with other antidiabetic drugs) (%) 16.8 –
Complications
Diabetic retinopathy (%) 7.2 –
Coronary heart disease (%) 12.7 6.4
Stroke (%) 7.5 4.7
Peripheral artery disease (%) 4.6 1.8
Diabetic neuropathy (%) 21.0 –
Heart failure (%) 5.7 2.8
Chronic renal failure (eGFR\60 mL/min/1.73 m2)a (%) 18.8 16.6
Microalbuminuria (30–300 mg/mL)b (%) 13.6 7.6
Macroalbuminuria ([300 mg/mL)b (%) 2.1 0.8
Use of healthcare resources
Primary care visits, mean (SD) 16.3 (15.3) 10.1 (11.9)
Hospitalizationsc, mean (SD), days 8.2 (13.3) 6.7 (11.5)
Referrals, mean (SD) 1.0 (1.4) 0.7 (1.1)
Diagnostic tests, mean (SD) 0.3 (0.5) 0.2 (0.6)
Laboratory parameters, mean (SD) 19.1 (18.5) 10.88 (14.4)
BMI Body mass index, eGFR estimated glomerular filtration rate using the MDRD (Modified Diet in Renal Disease) formula
a Patients with eGFR available: with type 2 diabetes 90,195; without diabetes 65,174
b Patients with albuminuria available: with type 2 diabetes 57,886; without diabetes 18,214
c Hospitalized patients: with type 2 diabetes 32,154; without diabetes 19,204
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non-diabetic subjects. The cost per patient is similar to that
reported in previous studies in Spain. For example, after
conversion to 2011 Euros, the annual costs reported in the
1998 CODE-2 study were €3363 [15], €3736 in the Bal-
lesta et al. study in 1999 [3], €1610 in the Spain Estimated
cost Ciberdem-Cabimer in Diabetes (SECCAID) study in
2010 [34], and €2229 in the study by Sicras-Mainar et al. in
2012 [19]. The SECCAID figure is notably lower, probably
due to the different methodology used (top-down), where
the total expenditure for the health system was divided by
the total estimated number of T2DM patients [34]. In our
study and in those by Ballesta et al., CODE-2, and Sicras-
Mainar et al. data were obtained directly from patient
records [3, 15, 19].
A cost comparison with other countries is difficult
because of differences between healthcare systems and
methodologies used. In Table S6 (Online Resource), the
results of studies that compared the costs in diabetic and
non-diabetic patients are shown. Costs recorded in two
studies conducted outside Spain, converted to 2011 €, are
notably higher: €4519 in Italy in 2003 [14], and €8117 in
the US in 2012 [5]. The Italian study [14] included items
corresponding to emergency care systems, and the US
study [5] included indirect costs related with mortality and
lost productivity, beyond the fact that the healthcare system
is mostly private. Finally, both studies included patients
with type 1 diabetes, and did not differentiate costs
between T2DM and type 1 diabetes. In our study, the
impact of the disease on costs was higher in men, in the
66–80 years age group, and in patients with complications.
This is in accordance with previous research showing that
costs may be substantially increased by cardiovascular and
microvascular complications [11, 35], especially ESRD
requiring dialysis and transplantation [35].
As in previous studies [2, 3, 7, 13, 14], the distribution
of costs by components was quite similar between diabetic
and non-diabetic subjects: the highest proportion of the
costs was distributed between hospital care, medication,
and primary care.
Previous studies comparing the costs of diabetic versus
non-diabetic populations have reported cost ratios consid-
erably higher than ours [5, 13, 14, 16–18, 36] (Online
Resource, Table S6), with the exception of the study by
Wire´hn et al. [13], in which the difference is only slightly
higher. In our study the cost of diabetic patients was 1.54
times higher than the cost of non-diabetics subjects, and









Total annual direct cost (€) 3110.1 (3065.8–3154.3) 1803.6 (1759.6–1847.3) 1306.6 (1244.3–1368.9) ?72.4
Primary care visits (€) 577.0 (573.9–580.0) 369.1 (366.7–371.4) 207.9 (204.0–211.9) ?56.3
Hospitalizations (€) 1303.1 (1262.0–1344.0) 801.6 (758.9–844.2) 501.4 (442.3–560.6) ?62.9
Referrals (€) 114.8 (113.9–115.7) 77.5 (76.8–78.3) 37.3 (36.2–38.4) ?48.1
Diagnostic tests (€) 82.4 (81.8–83.1) 46.5 (45.9–46.9) 35.9 (35.2–36.8) ?77.2
Self-monitoring blood test
strips (€)
50.1 (49.9–50.1) 0 50.1 (49.99–50.12) –
Medication (€) 925.0 (919.2–930.8) 489.2 (485.0–493.5) 435.8 (428.6–443.0) ?89.1
Dialysis (€) 57.8 (51.0–64.6) 19.7 (15.7–23.7) 38.1 (30.2–46.0) ?193.4
Table 3 Mean annual direct medical cost (95 % CI) in patients with T2DM according to the degree of glycaemic control
HbA1c[7 % ([53 mmol/mol)
(n = 42,632)




Total annual direct cost (€) 3296.5 (3229.6–3363.5) 2848.5 (2797.9–2899.0) 448.0 (365.7–530.4)
Primary care visits (€) 329.7 (326.2–333.3) 302.8 (299.9–305.8) 26.9 (22.3–31.5)
Hospitalizations (€) 1301.6 (1239.0–1364.2) 1131.2 (1084.9–1177.5) 170.4 (92.5–248.2)
Referrals (€) 128.4 (126.8–130.1) 120.0 (118.7–121.3) 8.4 (6.4–10.5)
Diagnostic tests (€) 92.2 (91.3–93.1) 88.2 (87.4–88.9) 4.0 (2.9–4.7)
Self-monitoring blood test
strips (€)
50.0 (49.9–50.1) 49.9 (49.8–50.0) 0.1 (-0.1 to ?0.2)
Medication (€) 1064.1 (1054.3–1073.8) 831.2 (823.5–838.8) 232.9 (220.5–245.3)
Dialysis (€) 23.7 (16.2–31.1) 41.9 (33.3–50.5) -18.2 (-6.8 to ?29.6)
a Good control was defined as HbA1c B7 % (B53 mmol/mol)
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this ratio dropped to 1.41 after adjustment for contributing
variables, namely age, gender, presence of cardiovascular
disease, heart failure, and dialysis or transplantation. This
ratio is quite below the 1.8 reported in a Swedish cost
analysis published in 2005 [13]. However, that study did
not differentiate between patients with type 1 diabetes and
type 2 diabetes; the ratio was only 1.36 in patients over
75 years, similar to the rate observed in our study (1.95 in
the over-80 age group), while in children it was 7.69 [13].
In an Italian study (the Turin Study, 2004) [14], the cost of
medication per person and year were 2.8 times higher in
diabetic patients, and represented 18.5 % of the total care
costs. Medication costs were 7.7 times higher in type 1
diabetes patients, and 2.5 times higher in T2DM patients
compared with non-diabetic subjects [14]. In Germany, in
two studies published by Ko¨ster et al. in 2001 and 2010
[16, 17], the cost ratio was the same in both groups, i.e. 1.9,
quite similar to our results (Online Resource, Table S6). In
contrast, results from studies performed in the US in 2007
and 2012 showed cost ratios of 3 and 2.9, respectively [5,
18].
A recently published study in the city of Badalona
(Catalonia, Spain) compared the costs of 3760 patients with
T2DM in a total of 26,845 patients managed at six primary
care centers and followed up prospectively during 2011
and 2012 [19]. The total costs of patients with T2DM after
2 years was €4458 compared with €2784 in non-diabetic
subjects, with a ratio (1.6) very similar to that observed in
our study (1.77). Although the total annual cost observed in
that study (€2229) was lower than in ours, possibly due to
Table 4 Multivariate analysis.
Variables influencing the direct
medical cost in patients with
T2DM. eGFR Estimated
glomerular filtration rate by
modification of diet in renal
disease (MDRD)
Odds ratio (95 % CI) P value
Age, years
\45 1.00
46–55 1.22 (1.12–1.33) \0.001
56–65 1.21 (1.12–1.32) \0.001
66–80 1.18 (1.09–1.27) 0.001
C81 1.25 (1.15–1.36) \0.001
Gender
Male 1.00
Female 0.92 (0.90–0.95) \0.001
T2DM duration
B10 years 1.00
[10 years 1.06 (1.02–1.10) 0.001
Treatment of T2DMs
No pharmacological treatment 1.00
Non-insulin antidiabetic agents 1.11 (1.07–1.15) \0.001
Insulina 1.64 (1.56–1.72) \0.001
Cardiovascular diseaseb 1.42 (1.37–1.47) \0.001
Heart failure 1.69 (1.59–1.80) \0.001
Kidney disease
Stages 1–3 1.00
Stage 4 (eGFR\30 mL min-1 1.73 m-2) 1.56 (1.36–1.79) \0.001
Stage 5 (eGFR\15 mL min-1 1.73 m-2 or dialysis) 10.35 (6.96–15.40) \0.001
Microvascular complicationsc 1.18 (1.13–1.22) \0.001
Obesity 1.10 (1.07–1.13) \0.001
Glycaemic control
HbA1c B7 % (B53 mmol mol-1) 1.00
HbA1c 7.01–8 % (53.1–63.9 mmol mol-1) 1.00 (0.97–1.04) 0.786
HbA1c 8.01–9 % (64–74.9 mmol mol-1) 1.05 (1.00–1.10) 0.052
HbA1c 9.01–10 % (75–85.8 mmol mol-1) 1.01 (0.94–1.07) 0.880
HbA1c[10 % ([85.8 mmol mol-1) 1.08 (1.01–1.16) 0.032
a Insulin alone or in combination with non-insulin antidiabetics
b Includes peripheral artery disease, stroke, and coronary heart disease
c Includes diabetic retinopathy, diabetic nephropathy (micro or macroalbuminuria), and diabetic
neuropathy
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differences in the methodology used for the allocation of
costs, the 60 % increase in the cost attributable to the
disease is similar to our results [19].
Regarding the impact of antidiabetic therapy, we must
stress that about a quarter of the patients in our study were
not receiving medication, and 35.4 % were receiving
monotherapy (usually metformin), and only 16.5 % were
receiving insulin. Therefore, the cost of antidiabetic drugs
was lower than in other studies and represented only 22 %
of the pharmacy costs. By comparison, for example, in the
Italian study [14], 26.2 % of patients were treated with
insulin, and 20.9 % were receiving non-pharmacological
treatment. In the Swedish study discussed above [13], the
percentage of patients receiving insulin is not mentioned;
however, the difference in costs for patients receiving
insulin suggests that it was high; in fact in the country-
specific Swedish section of the CODE-2 study 30 % of
patients received insulin [37]. However, in the Badalona
study, in which the annual cost was lower (€2229), the
proportion of patients receiving insulin was intermediate
(22.3 %) [19]. Of note, many studies omit data on drugs
other than insulin and oral antidiabetic agents. However,
polypharmacy is a frequent phenomenon among diabetic
patients and becomes more frequent with age and the long-
term evolution of the disease. Moreover, almost all diabetic
patients require not only hypoglycaemic treatment but also
treatment for comorbidities and cardiovascular risk factors
linked to diabetes. Our study confirms this increase in the
cost of other drugs (e.g., cardiovascular drugs) in diabetic
patients compared with non-diabetic subjects.
The methodological strengths of this study include the
use of a very large sample, the high quality data available
from a population database, and the fact that diabetic and
non-diabetic patients were individually matched and
managed in the same institution by the same physician,
meaning that the two groups were fully comparable.
Although there might have been estimation errors, these
would affect both groups equally, so that the conclusions
of the study would not be affected as regards the com-
parison between groups. Finally, in Spain, patients with
T2DM are controlled mainly by primary care profes-
sionals, which together with the gatekeeping role played
by Spanish general practitioners [38], means that the
information available from primary care is very compre-
hensive. Nevertheless, we want to remark that 14.131
subjects in the non-diabetic group and 2 patients in the
diabetic group had nominally no costs. This striking dif-
ference may be explained by the fact that since the
Spanish health care system is publicly funded, diabetic
patients could tend to use more health resources (e.g.,
material to manage the disease, follow-up visits, quarterly
blood analyses, annual reviews to screen for complica-
tions) than non-diabetic subjects. Moreover, this is a real-
life study and it is conceivable that non-diabetic subjects
are healthier (e.g., have less comorbid conditions) than
diabetic patients. To avoid producing a bias, especially
because this is a controlled study, we used a hurdle model
to take into account the difference in the number of zero
direct medical cost observations between diabetic and
non-diabetic subjects.
One limitation of this study, although common to all
studies using population-based databases, is the incom-
pleteness of some clinical variables. For example, data on
HbA1c were not available for about 25 % of patients, a
shortcoming that may have influenced the actual costs with
regard to glycaemic control. In relation to the possible
limitation of using the SIDIAP-Q database instead of the
whole database, it has been found previously that this
subset of patients is representative of the entire population
of Catalonia in terms of geographic and demographic
characteristics [23, 24]. One of the main limitations of our
study is that the costs of medical emergencies, including
hypoglycaemia, were not recorded. As the estimated cost
of an episode of severe hypoglycaemia may be as high as
€3500 [10], the increase in costs found in our study (1.77
times) may be underestimated. In addition, the study design
excluded individuals who died during the study period. It is
well known that mortality rates in diabetic patients are
higher than in the general population [1]. As long as dia-
betic patients need a comparatively more intensive and
expensive use of healthcare resources their inclusion could
have produced further incremental costs. Finally, this study
reports how incremental costs attributable to T2DM in the
context of a public health system are distributed, but we did
not assess the impact of indirect costs to society through
the quantification of lost productivity by temporary dis-
ability or costs due to premature retirement or death, which
may also involve a substantial increase in total expendi-
tures. Estimations of indirect costs are not often performed,
and findings diverge between studies, ranging between
30 % and 55 % of total costs [3, 5, 6]. Similarly, intangible
costs connected to diabetes such as reduced quality of life,
need of caregivers or family burden were not included. In
chronic diseases, these costs are often significant, but
quantifying them is very complex, and they are not inclu-
ded in the majority of studies.
Our results have implications for National Health Ser-
vice planners, as the increased prevalence of the disease in
developed countries is mainly due to population aging,
obesity, and the improved survival of people with diabetes
[1–4]. Healthcare costs associated with diabetes will
increase steadily in the coming years, and will have a
profound impact on society and on National Health System
expenditures. This trend has been highlighted in several
studies and should be taken into account by decision
makers when allocating health resources.
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In Spain, the number of people with diabetes in 2011 was
estimated to be slightly less than 3 million (a prevalence of
7.8 %) [1–3, 39]. As themean cost of caring for a patientwith
diabetes in our study was €3110.1, this means that the costs
of T2DM are approximately €10 billion (2,917,929 T2DM
patients 9 €3110.1). If we consider that the costs of patients
of the same age and sex without diabetes amount to €1803.6,
we obtain a figure of €1306 per patient attributable to T2DM;
therefore, the additional annual cost of diabetes for those
3 million patients, amounts to €3.9 billions.
Conclusion
In conclusion, the estimated higher costs for patients with
T2DM compared with non-diabetic subjects (72.4 %) are
due mainly to hospitalizations and medications, and are
higher among diabetic patients with poor glycaemic control
and macrovascular complications. The variables with the
greatest impact on costs were hospitalization, medication,
and visits to primary care centres. Hospitalization and
medication generated approximately 70 % of the differ-
ence in annual costs between the two groups.
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